Browsing: Psychedelics

The clinical evidence is real. The valuations are not. Compass Pathways: $560 million market cap, zero revenue. MindMed: up to $2 billion, zero revenue. Even Ozempic…

Smoking cessation research keeps evolving. For decades, public health strategies focused on abstinence, pharmaceutical nicotine replacement therapies, and behavioural interventions. Today, a growing body of evidence…

The Drug Enforcement Administration (DEA) is being put on notice—again—over prolonged delays in processing a petition to reschedule psilocybin from a doctor who wants to use…

“The pharmaceutical pathway and the natural medicine pathway are not competing rivers. They are tributaries of the same watershed.” By Shannon Hughes, Elemental Psychedelics via Colorado…

Sen. John Fetterman (D-PA) is giving some across-the-aisle credit to President Donald Trump for his administration’s moves to federally reschedule marijuana and accelerate therapeutic access to…

A bipartisan pair of members of Congress are continuing their push to expedite the availability of psychedelic therapies that they believe can aid military veterans and…

Another Hawaii House committee has approved a Senate-passed bill that would create a psychedelics task force responsible for studying and making policy recommendations on providing access…

“This is a careful bill for people, our veterans and first responders, who have carried extraordinary burdens.” By Rebecca Rivas, Missouri Independent After four years of…

A bipartisan group of U.S. senators have introduced a bill to promote research into the therapeutic potential psychedelics by creating a new office in the Department…

A new Senate bill is being filed that would promote research into the therapeutic potential psychedelics, aiming to create a new office in the Department of…